lactose has been researched along with ciprofloxacin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Akev, N; Birteksöz, S; Can, A; Gerçeker, A; Ozsoy, Y; Tunçel, T | 1 |
| Desai, TR; Finlay, WH; Hancock, RE; Wong, JP | 1 |
| Amighi, K; Hamdani, J; Moës, AJ | 1 |
| Dale, RM; Schnell, G; Wong, JP | 1 |
| Hu, Y; Li, X; Zhi, F | 1 |
| Ely, L; Finlay, WH; Löbenberg, R; Roa, W | 1 |
| Chang, J; Lee, H; Park, K; Park, YJ; Ryu, H; Yu, J | 1 |
| Abisheganaden, JA; Chandrasekaran, R; Chotirmall, SH; Hadinoto, K; Koh, MS; Lim, AYH; Low, TB; Roizman, D; Tan, GL; Teo, J; Tran, TT; Vidaillac, C; Yong, VFL; Yu, H | 1 |
| Britton, WJ; Chan, HK; Chang, RYK; Kutter, E; Li, J; Lin, Y; Morales, S | 1 |
| Ding, F; Guo, DS; Hu, B; Hu, XY; Hu, Y; Li, HB; Li, JJ; Wang, KR; Wang, W; Xu, H; Zhang, X | 1 |
11 other study(ies) available for lactose and ciprofloxacin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo studies on nasal preparations of ciprofloxacin hydrochloride.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Biological Availability; Calibration; Cellulose; Ciprofloxacin; Excipients; Female; Injections, Intravenous; Lactose; Male; Methylcellulose; Oxazines; Pharmaceutic Aids; Rabbits | 2000 |
A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling.
Topics: Administration, Inhalation; Amino Acid Sequence; Anti-Infective Agents; Ciprofloxacin; Drug Delivery Systems; Freeze Drying; Freeze Fracturing; Lactose; Liposomes; Microscopy, Electron, Scanning; Molecular Sequence Data; Particle Size; Powders | 2002 |
Development and evaluation of prolonged release pellets obtained by the melt pelletization process.
Topics: Ciprofloxacin; Delayed-Action Preparations; Diglycerides; Drug Compounding; Electron Probe Microanalysis; Excipients; Fatty Acids; Ketoprofen; Lactose; Microscopy, Electron, Scanning; Phenylephrine; Tablets | 2002 |
Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Burns; Ciprofloxacin; Drug Compounding; Excipients; Female; Lactose; Liposomes; Methylcellulose; Mice; Mice, Inbred BALB C; Nucleotides; Oxazines; Pseudomonas Infections; Survival Analysis; Wound Infection | 2004 |
Investigation of excipient and processing on solid phase transformation and dissolution of ciprofloxacin.
Topics: Anti-Infective Agents; Calorimetry, Differential Scanning; Cellulose; Ciprofloxacin; Delayed-Action Preparations; Drug Compounding; Excipients; Hypromellose Derivatives; Lactose; Methylcellulose; Povidone; Solubility; Tablets; Thermogravimetry; X-Ray Diffraction | 2007 |
Effervescent dry powder for respiratory drug delivery.
Topics: Administration, Inhalation; Aerosols; Carbon Dioxide; Carbonates; Chemistry, Pharmaceutical; Ciprofloxacin; Citric Acid; Desiccation; Drug Carriers; Drug Compounding; Enbucrilate; Excipients; Lactose; Microscopy, Confocal; Nanoparticles; Powders; Respiratory System Agents; Solubility; Technology, Pharmaceutical; Water | 2007 |
Prevalence and characteristics of lactose non-fermenting Escherichia coli in urinary isolates.
Topics: Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Lactose; Molecular Epidemiology; Multilocus Sequence Typing; Prevalence; Serogroup; Urine | 2014 |
A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Case-Control Studies; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Delivery Systems; Dry Powder Inhalers; Excipients; Humans; Lactose; Lung; Mannitol; Mucus; Permeability; Pseudomonas aeruginosa | 2018 |
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bacteriophages; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic Fibrosis; Dry Powder Inhalers; Excipients; Humans; Lactose; Nebulizers and Vaporizers; Particle Size; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 2019 |
Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Ciprofloxacin; Delayed-Action Preparations; Diabetes Mellitus; Drug Delivery Systems; Humans; Hypoxia; Lactose; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Ulcer | 2022 |